Matrix Metalloproteinases in the Pathogenesis of Viral Heart Disease

Trends in Cardiovascular Medicine

Volumn 19, Issue 1, 2009, Pages 21-26

  Marchant, David ^a   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GELATINASE B; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

DISEASE ASSOCIATION; HEART DISEASE; HUMAN; IMMUNE RESPONSE; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VIRUS INFECTION; VIRUS MYOCARDITIS;

ANIMALS; CHEMOKINES; CYTOKINES; EVIDENCE-BASED MEDICINE; HEART DISEASES; HUMANS; MATRIX METALLOPROTEINASES; MYOCARDITIS; VIRAL LOAD;

EID: 65749088909     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2009.04.001     Document Type: Review

References (26)

1. Calander A.M., Starckx S., Opdenakker G., et al. Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis. Microbes Infect 8 (2006) 1434-1439
2. Cheung C., Luo H., Yanagawa B., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc Pathol 15 (2006) 63-74
3. Cheung C.T., Deisher T.A., Luo H., et al. Neutralizing anti-4-1BBL treatment improves cardiac function in viral myocarditis. Lab Invest 87 (2007) 651-661
4. Cheung C., Marchant D., Walker E.K., et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 117 (2008) 1574-1582
5. Crocker S.J., Frausto R.F., Whitmire J.K., et al. Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. Am J Pathol 171 (2007) 1762-1773
6. Dean R.A., Cox J.H., Bellac C.L., et al. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood 112 (2008) 3455-3464
7. Elkington P.T., and Friedland J.S. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61 (2006) 259-266
8. Heymans S., Luttun A., Nuyens D., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5 (1999) 1135-1142
9. Heymans S., Lupu F., Terclavers S., et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166 (2005) 15-25
10. Heymans S., Pauschinger M., De Palma A., et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114 (2006) 565-573
11. Kishimoto C., and Abelmann W.H. In vivo significance of T cells in the development of Coxsackievirus B3 myocarditis in mice. Immature but antigen-specific T cells aggravate cardiac injury. Circ Res 67 (1990) 589-598
12. Li J., Schwimmbeck P.L., Tschope C., et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 56 (2002) 235-247
13. Lovelock J.D., Baker A.H., Gao F., et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 288 (2005) H461-H468
14. Manis J.P. Knock out, knock in, knock down-genetically manipulated mice and the Nobel Prize. N Engl J Med 357 (2007) 2426-2429
15. Marchant D., Cheung C., Carthy J., et al. 2009. MatrixMetalloproteinase-12 expression is a critical mediator of the innate antiviral immune response. In review.
16. Mastroianni C.M., and Liuzzi G.M. Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 13 (2007) 449-459
17. McQuibban G.A., Gong J.H., Tam E.M., et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289 (2000) 1202-1206
18. Nelissen I., Martens E., Van den Steen P.E., et al. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain 126 (2003) 1371-1381
19. Opavsky M.A., Penninger J., Aitken K., et al. Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection. Circ Res 85 (1999) 551-558
20. Parks W.C., Wilson C.L., and Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4 (2004) 617-629
21. Pauschinger M., Rutschow S., Chandrasekharan K., et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail 7 (2005) 444-452
22. Renckens R., Roelofs J.J., Florquin S., et al. Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 176 (2006) 3735-3741
23. Schnurr D.P., Cao Y., and Schmidt N.J. Coxsackievirus B3 persistence and myocarditis in N:NIH(S) II nu/nu and +/nu mice. J Gen Virol 65 Pt 7 (1984) 1197-1201
24. Schonbeck U., Mach F., and Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161 (1998) 3340-3346
25. Van Den Steen P.E., Wuyts A., Husson S.J., et al. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 270 (2003) 3739-3749
26. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839